Splash Beverage Group, a company best known for its portfolio of beverage brands, is making a sharp pivot into the pharmaceutical space. The firm announced a 20-year global licensing agreement to develop and commercialize CannEpil, a cannabinoid-based investigational therapy designed to treat drug-resistant epilepsy. The deal marks a significant strategic shift for Splash, which has historically focused on alcoholic and non-alcoholic drinks.
Deal Structure and Funding
Under the terms of the agreement, Splash has secured exclusive worldwide rights to CannEpil, which is already available in some international markets. To support the expansion, the company lined up $1 million in development funding from C/M Capital Partners, a financing firm. Additionally, Splash agreed to issue $5.5 million in preferred equity to Mercer Street Global Opportunity Fund, an investment fund that will also forgive certain outstanding debts as part of the restructuring.
As part of the deal, Argent, the original developer of CannEpil, will earn a 15% royalty on net revenue from sales. This structure is common in pharmaceutical licensing, where the licensor receives a percentage of sales in exchange for granting rights to a drug candidate.
What Is CannEpil?
CannEpil is a cannabinoid-based therapy aimed at patients with drug-resistant epilepsy, a condition where seizures do not respond to standard anti-epileptic medications. The product is still in the investigational stage, meaning it has not yet received full regulatory approval in major markets like the United States. However, it is already being sold in certain countries, giving Splash a revenue stream while it pursues broader approvals.
The therapy is part of a growing field of cannabinoid-based medicines, which have gained attention in recent years for their potential to treat conditions like epilepsy, chronic pain, and anxiety. The most well-known example is Epidiolex, a CBD-based drug approved by the U.S. Food and Drug Administration (FDA) for certain forms of epilepsy.
Strategic Pivot for Splash
Splash Beverage Group has built its business around brands like Copa Di Vino wine by the glass and Sipz, a line of ready-to-drink cocktails. The move into pharmaceuticals represents a major departure from its core operations. For investors, this raises questions about the company's ability to execute in a highly regulated industry where clinical trials, regulatory approvals, and manufacturing standards are far more complex than in the beverage sector.
However, the deal also opens up a potentially larger addressable market. The global epilepsy drugs market is expected to grow steadily, driven by rising diagnosis rates and the need for new treatments for patients who do not respond to existing therapies. By securing a 20-year license, Splash is betting that CannEpil can carve out a niche in this space.
What It Means for Investors
For everyday investors, this deal is a reminder that small-cap companies often make bold strategic pivots that can dramatically change their risk profile. Splash is now a hybrid company—part beverage, part biotech. The $1 million in development funding provides near-term capital to advance CannEpil, but the $5.5 million in preferred equity issuance will dilute existing shareholders. Preferred equity typically gives investors priority over common shareholders in dividends and liquidation, meaning common stock holders could see their ownership stake reduced.
The 15% royalty to Argent is also a significant ongoing cost. While royalties are standard in pharma licensing, they eat into profit margins. Investors should watch for updates on regulatory progress, clinical trial results, and any partnerships with larger pharmaceutical companies that could accelerate commercialization.
In the broader market context, this deal comes amid a wave of interest in cannabinoid-based therapies. While many cannabis companies have struggled with profitability, pharmaceutical applications have shown more promise due to clearer regulatory pathways and insurance reimbursement potential. Splash's success will depend on its ability to navigate these complexities.
For now, the stock is likely to see increased volatility as the market digests the news. Investors should monitor the company's upcoming filings for details on the preferred equity terms and any milestones tied to the development funding.
Looking Ahead
Splash Beverage Group plans to use the development funding to expand CannEpil into the U.S. and other major regions. The company will need to conduct clinical trials, seek regulatory approvals, and build a sales infrastructure—all of which require time and capital. The 20-year duration of the deal gives Splash a long runway, but the path to profitability is uncertain.
As with any early-stage biotech investment, the risks are high. But for a beverage company making a bold pivot, the potential rewards could be substantial if CannEpil gains traction. Investors should keep an eye on regulatory milestones and partnership announcements in the coming months.
